Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni')

Drug Testing and Analysis

Volumn 6, Issue 7-8, 2014, Pages 684-695

  Brandt, Simon D ^a   Baumann, Michael H ^b   Partilla, John S ^b   Kavanagh, Pierce V ^c   Power, John D ^c   Talbot, Brian ^c   Twamley, Brendan ^c,d   Mahony, Olivia ^e   O'Brien, John ^d   Elliott, Simon P ^f   Archer, Roland P ^g   Patrick, Julian ^h   Singh, Kuldip ⁱ   Dempster, Nicola M ^a   Cosbey, Simon H ^j  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c ST JAMES S HOSPITAL   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^f Inverness Medical Innovations   (United States)

^g States Analyst's Laboratory Longue Rue   (France)

^h Scientific Supplies Ltd   (United Kingdom)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j FORENSIC SCIENCE NORTHERN IRELAND   (United Kingdom)

more..

Author keywords

4 methylaminorex; Aminorex; Internet; Monoamine transporters; New psychoactive substances; para methyl 4 methylaminorex; Psychostimulants; Synaptosomes

Indexed keywords

BRAIN; CONTROLLED DRUG DELIVERY; CRYSTAL STRUCTURE; DRUG INTERACTIONS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TARGETED DRUG DELIVERY;

4-METHYLAMINOREX; AMINOREX; DESIGNER DRUGS; DRUG ADDICTION; MONITORING CENTERS; MONOAMINE TRANSPORTER; NEW PSYCHOACTIVE SUBSTANCE; PARA-METHYL-4-METHYLAMINOREX; PSYCHOSTIMULANTS; SYNAPTOSOME;

GAS CHROMATOGRAPHY;

4 METHYL 4 METHYLAMINOREX; 4 METHYLAMINOREX; AMINOREX; DESIGNER DRUG; DEXAMPHETAMINE; DOPAMINE TRANSPORTER; MONOAMINE; NEW DRUG; NORADRENALIN TRANSPORTER; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; 4-METHYLAMINOREX; CENTRAL STIMULANT AGENT; OXAZOLE DERIVATIVE; PARA-METHYL-4-METHYLAMINOREX; STREET DRUG; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CENTRAL NERVOUS SYSTEM; CIS ISOMER; CRYSTAL STRUCTURE; DRUG DEPENDENCE; DRUG MARKETING; DRUG MONITORING; DRUG STRUCTURE; DRUG SYNTHESIS; EUROPE; GAS CHROMATOGRAPHY; INTERNET; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; ISOMERISM; MALE; METABOLISM; SPRAGUE DAWLEY RAT; SYNAPTOSOME;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; HUMANS; ISOMERISM; MALE; MODELS, MOLECULAR; OXAZOLES; RATS; RATS, SPRAGUE-DAWLEY; STREET DRUGS; SYNAPTOSOMES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84904578076     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1668     Document Type: Article

References (51)

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Action on new drugs. Available at: http://www.emcdda.europa.eu/activities/action-on-new-drugs [11 March 2014].
2. EMCDDA-Europol. EU drug markets report: A strategic analysis. Avilable at: http://www.emcdda.europa.eu/publications/joint-publications/drug-markets [11 March 2014].
3. United Nations Office on Drugs and Crime (UNODC). The challenge of new psychoactive substances. A Report from the Global SMART Programme, 2013. Available at: www.unodc.org/documents/scientific/NPS_2013_SMART.pdf [11 March 2014].
4. Council Decision 2005/387/JHA of 20 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances. Official J. EU 2005, L 127/32.
5. L.L. Ioannides-Demos, J. Proietto, A.M. Tonkin, J.J. McNeil . Safety of drug therapies used for weight loss and treatment of obesity. Drug Safety. 2006, 29, 277.
6. G.I. Poos, J.R. Carson, J.D. Rosenau, A.P. Roszkowski, N.M. Kelley, J. McGowin . 2-Amino-5-aryl-2-oxazolines. Potent new anorectic agents. J. Med. Chem. 1963, 6, 266.
7. G.I. Poos . 2-Amino-5-acryloxazoline products. U.S. Patent 3161650, 1964.
8. A.P. Roszkowski, N.M. Kelley . A rapid method for assessing drug inhibition of feeding behavior. J. Pharmacol. Exp. Ther. 1963, 140, 367.
9. H.P. Gurtner . Aminorex and pulmonary hypertension. A review. Cor Vasa 1985, 27, 160.
10. H.P. Gurtner . Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? Bull. Eur. Physiopathol. Respir. 1979, 15, 897.
11. R.B. Rothman, M.A. Ayestas, C.M. Dersch, M.H. Baumann . Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 1999, 100, 869.
12. Y. Dempsie, M.R. MacLean . Pulmonary hypertension: therapeutic targets within the serotonin system. Brit. J. Pharmacol. 2008, 155, 455.
13. M.E. Brewster, F.T. Davis . Appearance of aminorex as a designer analog of methylaminorex. J. Forensic Sci. 1991, 36, 587.
14. S.A. Barker . The formation of aminorex in racehorses following levamisole administration. A quantitative and chiral analysis following synthetic aminorex or levamisole administration vs. aminorex-positive samples from the field: a preliminary report. J. Vet. Pharmacol. Ther. 2009, 32, 160.
15. C. Hess, N. Ritke, S. Broecker, B. Madea, F. Musshoff . Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS. Anal. Bioanal. Chem. 2013, 405, 4077.
16. C. Hess, N. Ritke, K. Sydow, L.-M. Mehling, H. Ruehs, B. Madea, F. Musshoff . Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole. Drug Test. Anal. 2014, DOI: 10.1002/dta.1619
17. S.B. Karch, F. Mari, V. Bartolini, E. Bertol . Aminorex poisoning in cocaine abusers. Int. J. Cardiol. 2012, 158, 344.
18. F.T. Davis, M.E. Brewster . A fatality involving U4Euh, a cyclic derivative of phenylpropanolamine. J. Forensic Sci. 1988, 33, 549.
19. A.W. By, B.A. Dawson, B.A. Lodge, W.W. Sy . Spectral distinction between cis- and trans-4-methylaminorex. Forensic Sci. Int. 1989, 43, 83.
20. R.F.X. Klein, A.R. Sperling, D.A. Cooper, T.C. Kram . The stereoisomers of 4-methylaminorex. J. Forensic Sci. 1989, 34, 962.
21. 1H NMR spectral simplification with chiral solvating agents and with achiral and chiral lanthanide shift reagents. cis-4, 5-Dihydro-4-methyl-5-phenyl-2-oxazolamine, "cis-4-methylaminorex, " a potent stimulant and anorectic. Spectrosc. Lett. 1990, 23, 589.
22. A. Kankaanpää, E. Meririnne, S. Ellermaa, K. Ariniemi, T. Seppälä . Detection and assay of cis- and trans-isomers of 4-methylaminorex in urine, plasma and tissue samples. Forensic Sci. Int. 2001, 121, 57.
23. W.R. Rodriguez, R.A. Allred . Synthesis of trans-4-methylaminorex from norephedrine and potassium cyanate. Microgram J. 2005, 3, 154.
24. F.T. Noggle Jr., C.R. Clark, J. DeRuiter . Liquid chromatographic and spectral analysis of the stereoisomers of dimethylaminorex. J. AOAC Int. 1992, 75, 423.
25. M. Takagi, K. Ishimitsu, T. Nishibe . Preparation of oxa(thia)zolidine derivative as anti-inflammatory agents. International Patent Application WO2001072723, 2001.
26. EMCDDA-Europol. Dangerous synthetic drugs hit the EU market. Available at: http://www.emcdda.europa.eu/news/2014/europol-emcdda1 [05 March 2014].
27. EMCDDA-Europol. EMCDDA-Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012). Available at: http://www.emcdda.europa.eu/publications/implementation-reports/2012 [10 March 2014].
28. S. Cosbey, S. Kirk, M. McNaul, L. Peters, B. Prentice, A. Quinn, S.P. Elliott, S.D. Brandt, R.P. Archer . Multiple fatalities involving a new designer drug - para-methyl-4-methylaminorex. J. Anal. Toxicol. 2014 (in press)
29. R.B. Rothman, M.H. Baumann . Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol. 2003, 479, 23.
30. G.M. Sheldrick, SHELXTL Version 6.10. Bruker AXS Inc., Madison, Wisconsin, USA.
31. R.B. Rothman, N. Vu, J.S. Partilla, B.L. Roth, S.J. Hufeisen, B.A. Compton-Toth, J. Birkes, R. Young, R.A. Glennon . In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J. Pharmacol. Exp. Ther. 2003, 307, 138.
32. M.H. Baumann, M.A. Ayestas Jr, J.S. Partilla, J.R. Sink, A.T. Shulgin, P.F. Daley, S.D. Brandt, R.B. Rothman, A.E. Ruoho, N.V. Cozzi . The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37, 1192.
33. Serotoni. Available at: http://serotoni.info [06 April 2014].
34. G.L. Henderson, M.R. Harkey, Y.T. Chueh . Metabolism of 4-methylaminorex ("EU4EA") in the rat. J. Anal. Toxicol. 1995, 19, 563.
35. C. Schmidt . Einwirkung von Phtalimidkalium auf einige sauerstoffhaltige Halogenverbindungen. Ber. Deut. Chem. Ges. 1889, 22, 3249.
36. Y.L. Han, H.W. Hu . A convenient synthesis of aminomethyl ketones (α-amino ketones). Synthesis 1990, 615.
37. G. Fodor, K. Koczka . 155. The stereochemical course of the conversion of 2-ureidoalcohols into oxazolidines. Part I. J. Chem. Soc. 1952, 850.
38. McNeill Laboratories Inc. Procédé de production de nouvelles 2-aminooxazolines et leurs sels d'addition avec les acides, et produits obtenus. Belgian Patent 628803, 1963.
39. McNeill Laboratories Inc. Composé de la classe des 2-amino-5-aryl-oxazolines et compositions pharmaceutiques le contenant. French Patent 2448M, 1964.
40. 2-Amino-5-aryloxazoline compositions and methods of using same. US Patent 3278382A, 1966.
41. D.A. Cooper, Future synthetic drugs of abuse. in Proceedings of the international symposium on the forensic aspects of controlled substances: March 28 - April 1, (Ed: R.T. Castonguay ). Laboratory Division, Federal Bureau of Investigation, US Dept. of Justice: Washington, DC, 1988, pp. 79.
42. C.F. Bunker, M. Johnson, J.W. Gibb, L.G. Bush, G.R. Hanson . Neurochemical effects of an acute treatment with 4-methylaminorex: a new stimulant of abuse. Eur. J. Pharmacol. 1990, 180, 103.
43. R.A. Glennon, B. Misenheimer . Stimulus properties of a new designer drug: 4-methylaminorex ("U4Euh"). Pharmacol. Biochem. Behav. 1990, 35, 517.
44. R.S. Mansbach, C.A. Sannerud, R.R. Griffiths, R.L. Balster, L.S. Harris . Intravenous self-administration of 4-methylaminorex in primates. Drug Alcohol Depend. 1990, 26, 137.
45. G.R. Hanson, C.F. Bunker, M. Johnson, L. Bush, J.W. Gibb . Response of monoaminergic and neuropeptide systems to 4-methylaminorex: A new stimulant of abuse. Eur. J. Pharmacol. 1992, 218, 287.
46. R. Young, R.A. Glennon . Cocaine-stimulus generalization to two new designer drugs: methcathinone and 4-methylaminorex. Pharmacol. Biochem. Behav. 1993, 45, 229.
47. K. Batsche, C.R. Ashby Jr., C. Lee, J. Schwartz, R.Y. Wang . The behavioral effects of the stereoisomers of 4-methylaminorex, a psychostimulant, in the rat. J. Pharmacol. Exp. Ther. 1994, 269, 1029.
48. C.R. Ashby Jr., H. Pan, Y. Minabe, A. Toor, L. Fishkin, R.Y. Wang . Comparison of the action of the stereoisomers of the psychostimulant 4-methylaminorex (4-MAX) on midbrain dopamine cells in the rat: an extracellular single unit study. Synapse 1995, 20, 351.
49. B.R. Russell, R.A. Beresford, D.M. Schmierer, N. McNaughton, C.R. Clark . Stimulus properties of some analogs of 4-methylaminorex. Pharmacol. Biochem. Behav. 1995, 51, 375.
50. Y. Zheng, B. Russell, D. Schmierer, R. Laverty . The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice. J. Pharm. Pharmacol. 1997, 49, 89.
51. R.M. Goodman . Methods of decongesting the nose without adverse stimulant effects. US Patent 4980364A, 1990.